GlassScriptPhysician profile
Alexander Rotenberg
NPI 1154348043
$34,410.91
in general payments reported to CMS, 2019-2025
11 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,699 · 2020: $5,319 · 2022: $7,681 · 2023: $54.30 · 2024: $17K · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $757 · Food and Beverage: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,465.98 |
| Travel and Lodging | $757.02 |
| Food and Beverage | $488.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $13,835.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $9,056.00 | 2024 | |
| Trevena, INC. | $4,981.02 | 2022 | |
| Allergan, INC. | $3,100.00 | 2019 | |
| Alkermes, INC. | $2,899.98 | 2024 | |
| Biomarin Pharmaceutical INC. | $172.20 | 2019 | |
| Sk Life Science, INC. | $148.07 | 2024 | Xcopri |
| Ucb, INC. | $124.05 | 2019-2023 | Nayzilam |
| Vertex Pharmaceuticals Incorporated | $64.60 | 2019-2025 | |
| Immedica Pharma US, INC. | $29.99 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Rotenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.